Literature DB >> 15664922

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Hang Xie1, Ihsan Gursel, Bruce E Ivins, Manmohan Singh, Derek T O'Hagan, Jeffrey B Ulmer, Dennis M Klinman.   

Abstract

To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664922      PMCID: PMC547063          DOI: 10.1128/IAI.73.2.828-833.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  US soldiers refuse to fall in line with anthrax vaccination scheme.

Authors:  Tinker Ready
Journal:  Nat Med       Date:  2004-02       Impact factor: 53.440

Review 2.  Innate immunity and biodefence vaccines.

Authors:  Nicholas M Valiante; Derek T O'Hagan; Jeffrey B Ulmer
Journal:  Cell Microbiol       Date:  2003-11       Impact factor: 3.715

3.  Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Authors:  Phillip R Pittman; Gina Kim-Ahn; Dominique Y Pifat; Kevin Coonan; Paul Gibbs; Steve Little; Judith G Pace-Templeton; Robert Myers; Gerald W Parker; Arthur M Friedlander
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

4.  Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

Authors:  T R Jones; N Obaldia; R A Gramzinski; Y Charoenvit; N Kolodny; S Kitov; H L Davis; A M Krieg; S L Hoffman
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

5.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

6.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

Authors:  Scott A Halperin; Gary Van Nest; Bruce Smith; Simin Abtahi; Heather Whiley; Joseph J Eiden
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

7.  Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios.

Authors:  D A Geier; M R Geier
Journal:  Clin Exp Rheumatol       Date:  2002 Mar-Apr       Impact factor: 4.473

8.  Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.

Authors:  S L Welkos; A M Friedlander
Journal:  Microb Pathog       Date:  1988-08       Impact factor: 3.738

9.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.

Authors:  Mathias Heikenwalder; Magdalini Polymenidou; Tobias Junt; Christina Sigurdson; Hermann Wagner; Shizuo Akira; Rolf Zinkernagel; Adriano Aguzzi
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles.

Authors:  Kimberly S Denis-Mize; Marc Dupuis; Manmohan Singh; Carolyn Woo; Mildred Ugozzoli; Derek T O'Hagan; John J Donnelly; Gary Ott; Donald M McDonald
Journal:  Cell Immunol       Date:  2003-09       Impact factor: 4.868

View more
  34 in total

1.  A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

Review 2.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.

Authors:  Jigna D Patel; Ronan O'Carra; Julia Jones; Jerold G Woodward; Russell J Mumper
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

6.  Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.

Authors:  Dennis M Klinman; Sven Klaschik; Koji Tomaru; Hidekazu Shirota; Debra Tross; Hidekazu Ikeuchi
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 7.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

Review 8.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

9.  Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.

Authors:  Dennis M Klinman; Debra Currie; Gloria Lee; Vanessa Grippe; Tod Merkel
Journal:  Microbes Infect       Date:  2007-08-10       Impact factor: 2.700

10.  Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin.

Authors:  John M Thomas; Scott T Moen; Bryan T Gnade; Diego A Vargas-Inchaustegui; Sheri M Foltz; Giovanni Suarez; Hans W Heidner; Rolf König; Ashok K Chopra; Johnny W Peterson
Journal:  Clin Vaccine Immunol       Date:  2009-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.